“The nature of science has changed in recent years and become more transdisciplinary. It doesn’t follow the traditional, rigid discipline that it has in the past. We need different types of facilities and spaces. That will be an increasing issue going forward for NIH. Almost three-quarters of buildings are more than 20 years old, and they are not designed and constructed to support where science is going.”
Kenneth Kizer, who chaired the Committee on Assessing the Capital Needs of the NIH. A two-year study concluded that the NIH’s Bethesda, Md., campus needs a $1.3 billion upgrade to its buildings and facilities

“We have a really rich portfolio of targets. But in order to develop drugs efficiently against our dozens of targets, we needed a partnership that would allow us to go through these targets in a much more efficient manner than the traditional empirical small-molecule testing in biochemical assays.”
Carla Grandori, founder and CEO of Sengine Precision Medicine Inc., which partnered with Atomwise Inc. to use its artificial intelligence platform to develop drugs for Sengine’s targets

“It’s amazingly effective at clearing one of the toxins which is extremely neurotoxic – ammonia. Apart from that we also clear out the other toxins that accumulate in these patients.”
Meriam Kabbaj, co-founder and chief operating officer, Versantis AG, which raised CHF16 million (US$16.1 million) in a series B round to progress clinical trials of a liposomal-based fluid in development for eliminating ammonia and other toxic metabolites from the circulation of patients in acute stages of liver failure who are undergoing peritoneal dialysis

No Comments